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Abstract
Background: Incorporation of exon 11 of the insulin receptor gene is both developmentally and
hormonally-regulated. Previously, we have shown the presence of enhancer and silencer elements
that modulate the incorporation of the small 36-nucleotide exon. In this study, we investigated the
role of inherent splice site strength in the alternative splicing decision and whether recognition of
the splice sites is the major determinant of exon incorporation.
Results: We found that mutation of the flanking sub-optimal splice sites to consensus sequences
caused the exon to be constitutively spliced in-vivo. These findings are consistent with the exon-
definition model for splicing. In-vitro splicing of RNA templates containing exon 11 and portions of
the upstream intron recapitulated the regulation seen in-vivo. Unexpectedly, we found that the
splice sites are occupied and spliceosomal complex A was assembled on all templates in-vitro
irrespective of splicing efficiency.
Conclusion:  These findings demonstrate that the exon-definition model explains alternative
splicing of exon 11 in the IR gene in-vivo but not in-vitro. The in-vitro results suggest that the
regulation occurs at a later step in spliceosome assembly on this exon.
Background
The human insulin receptor (IR) is encoded by a single
gene that is located on chromosome 19 and composed of
22 exons. The mature IR exists as two isoforms, designated
A and B, which result from alternative splicing of the pri-
mary transcript. The A isoform lacking exon 11 binds both
insulin and IGF-II with high affinity and is expressed
ubiquitously; the B isoform containing exon 11 only
binds insulin and is expressed predominantly in liver,
muscle, adipocytes, and kidney [1,2]. The alternatively
spliced exon 11 encodes a 12-amino acid segment (resi-
dues 717–728) of the   subunit of receptor that disrupts
binding to IGF-II [3]. Inclusion of this exon is develop-
mentally and hormonally-regulated and is altered in a
number of disease states, such as type II diabetes and
myotonic dystrophy, that are associated with insulin
resistance [4-10]. The dysregulation of the alternative
splicing of the IR may have important consequences for
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insulin-sensitivity and responsiveness. In previous stud-
ies, we have investigated the regulation of splicing of this
exon in-vivo using a model minigene system containing
exons 10, 11, and 12 and parts of the intervening introns
[11]. Recognition of the exon appears to be rate-limiting
as partially spliced RNAs were identified that lacked
intron 10 but retained intron 11, but none were observed
lacking only intron 11. We furthermore identified both
enhancer and silencer elements in the precursor RNA that
modulated incorporation of exon 11.
Splicing of pre-mRNA depends on the presence of rela-
tively short RNA sequence elements, the 3' splice site, the
5' splice site, and the branch point sequence (reviewed in
ref [12]). Removal of the intron occurs via two transester-
ification reactions; the first occurring between the 5' splice
site and the 2'-OH of the branch point adenine, the sec-
ond occurring between the 3'-OH of the 5' exon and the
3' exon. The sites are aligned for accurate excision by a
complex network of RNA and protein interactions involv-
ing both splice sites and the branch point sequence in a
large complex called the spliceosome. Assembly of the
spliceosome begins with recognition of the 5' splice site
by the U1 snRNP by base pairing. U2 snRNP is recruited
to the branch point sequence by the accessory factor U2AF
[13-15]. This factor is a heterodimer of a 65 kDa subunit
that recognizes a polypyrimidine tract and a 35 kDa sub-
unit that recognizes the 3' splice site and promotes bind-
ing of U2AF-65 [16-18]. Binding of U2AF to the 3' splice
site is further stabilized by the branch point binding pro-
tein BBP/SF1 that also interacts with the Prp40 subunit of
the U1 snRNP [19-21]. The complex containing the pre-
RNA, and the U1 and U2 snRNPs is called the pre-spliceo-
somal complex or complex A in mammals. This complex
then recruits the U4/U5/U6 tri-snRNP to form complex B,
and the spliceosome undergoes a number of rearrange-
ments to create the catalytically active splicing complex C.
Each of the steps in assembly is facilitated by numerous
extrinsic factors that may or may not become part of the
final spliceosome [22].
Alternative cassette exons often contain splice sites that
are weak matches to the consensus sequence and muta-
tion of the sites to the consensus in many cases causes the
exon to be spliced constitutively. Recognition of these
splice sites is inherently poor but can be modulated by cis-
acting elements in the RNA that bind trans-acting splicing
factors (reviewed in ref [23]). These elements can either
have a positive (splicing enhancers) or negative (splicing
silencers) effect on splicing. Differences in the expression
level, or activity of the trans-acting factors modulates the
recognition of the alternative exon and leads to develop-
mental or tissue specific differences in splicing. One
model for enhancer function, the U2AF recruitment
model, involves the stabilization of the interaction of the
subunits of U2AF with the branch point sequence and 3'
splice site. SR proteins have been shown to increase cross-
linking of U2AF-65 to the 3' splice site by interacting with
the 35 kDa subunit U2AF-35 [24]. SR proteins have also
been shown to interact with the U1-70K protein that is a
component of the U1-snRNP [25,26]. These interactions
have led to the proposal that SR proteins bridge splice
sites across introns, or exons, by binding to components
of both the 5' and 3' splice sites. A number of studies have
shown that the ability of SR proteins to bind to exonic
enhancers correlates with their ability to activate splicing
from weak splice sites, the inference being that the SR pro-
teins were recruiting factors to the splice sites [27-30]. This
has lead to the notion that alternative splicing is regulated
at the level of splice site recognition. Consistent with this
idea, a number of splicing factors have been shown to act
as silencers by blocking access to splice sites and mutation
of constitutive splice sites abrogates recognition of the
sites [31,32]. In this study, we tested the exon-definition
model on exon 11 of the IR gene by mutating the splice
sites flanking the exon. We also investigated the recogni-
tion of these splice sites by the splicing apparatus in-vitro
and found that pre-spliceosmal splicing complexes are
formed on all sites irrespective of splicing efficiency.
Results
Mutation of splice sites surrounding exon 11 alters its 
incorporation into mRNA
An inspection of the 5' splice site sequences of both exons
10 and 11 highlighted a number of differences from the
consensus sequence that is complementary to the U1
snRNA. Analysis of splice site strength using the Shapiro-
Senapathy method gave scores of 85.4 and 83.0 (out of
100) for the two 5' splice sites (Fig. 1A). This suggested to
us that the sites encompassing exon 11 were likely to be
inefficient. Splice sites at the 3' end of exons are less
defined but the length of the poly-pyrimidine tract is often
an indication of splice site strength. Both 3' splice sites in
the IR minigene contain a number of purine nucleotide
insertions in the polypyrimidine tract, but still scored 94.0
and 90.6. The scores suggested that these sites would be
active splice sites, but we wanted to test whether they were
less than optimal. Each 5' splice site was mutated to the
consensus sequence and the purine insertions in the 3'
splice sites were mutated to thymidines thus lengthening
the tracts.
The mutant minigenes were tested by transfection into
HepG2 and HeLa cells. RNA was extracted and subjected
to reverse-transcription and PCR using primers described
previously [11]. To ensure that only mature mRNA was
analyzed, RNA was captured on oligo-dT before reverse
transcription. The parental minigene containing the 2.3
Kb intron 10 showed 42% skipping of exon 11 in HepG2
cells and 66% in HeLa cells (pIRB, Fig. 1A). Thus, exon 11BMC Molecular Biology 2004, 5:7 http://www.biomedcentral.com/1471-2199/5/7
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in the minigene is recognized more efficiently in HepG2
cells than HeLa cells, which is consistent with the known
splicing of the endogenous IR gene in these cells. We have
previously shown that mutation of a single G residue at
position -10 in the pyrimidine tract did not alter exon
incorporation but increasing the length of the polypyrimi-
dine tract caused the exon to be recognized constitutively
in both HepG2 and HeLa cells (pIRB.MC0). Similarly,
mutation of the 5' splice site on exon 11 to the consensus
caused the exon to be spliced constitutively (pIRB.MC1,
Fig. 1A). Therefore, strengthening either splice site flank-
ing exon 11 caused the exon to be recognized more effi-
ciently. Conversely, mutation of the 5' splice site on exon
10 or increasing the length of the polypyrimidine tract on
exon 12 caused exon skipping to increase in both cell
types (pIRB.MC15 and pIRB.MC11, respectively). Increas-
ing the strength of the distal 3' splice site in the presence
of a strong proximal site did not cause skipping of exon 11
(pIRB.MC5), however, indicating that exon skipping is
Skipping of exon 11 requires sub-optimal splice sites Figure 1
Skipping of exon 11 requires sub-optimal splice sites. Exons 10, 11, and 12 and the sequences of the splice sites at the 
ends of the introns are shown. Panel A: The 5' splice sites of exon 10 and exon 11 are 5/7 and 4/7 matches to the consensus 
sequence, respectively. The splice site scores (out of 100) are indicated above each site. These sites were altered to match the 
consensus sequence in the parental IR minigene (pIRB) that contains 2.3 Kb of intron 10 and 360 bp of intron 11 giving mini-
genes pIRB.MC15 and pIRB.MC1. The 3' splice sites of exon 11 and exon 12 contain a number of purine residues interspersed 
in the polypyrimidine tracts. These residues were mutated to thymidines to strengthen each 3' splice site giving minigenes 
pIRB.MC0 and pIRB.MC11. Mutated residues are shown in bold and underlined. The intervening sequence is omitted and indi-
cated by the slashes. The minigenes were transfected into HepG2 and HeLa cells. RNA was extracted and mRNA subjected to 
reverse transcription and amplification by PCR. The columns to the right show the percentage of skipping of exon 11 in either 
cell line. Results are the mean of four independent experiments. Asterisks indicate statistical significance versus the parental 
minigene pIRB (*p < 0.05, ***p < 0.001). Panel B: The same mutations were introduced into the splice sites of intron 10 in mini-
genes containing internal deletions of intron 10. Minigene pIRA contains the purine-rich enhancer (GA) and the inhibitor 
(INH), minigene pIRK only contains the inhibitor (INH). Sequences of the 5' and 3' splice sites of intron 10 are shown. Inter-
vening sequence is indicated by dashed lines. Both pIRA and pIRK contain the identical intron 11 and exon 12 sequences as 
pIRB in Panel A but these sequences are omitted for clarity. These minigenes were transfected into HepG2 and HeLa cells as 
above. The percentage of skipping of exon 11 is given in the columns on the right. Results are the mean of four independent 
experiments. Asterisks indicate statistical significance versus the minigene with natural splice sites * p < 0.05).BMC Molecular Biology 2004, 5:7 http://www.biomedcentral.com/1471-2199/5/7
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only observed in the presence of non-consensus splice
sites on exon 11.
These mutations were also tested in minigenes containing
internal deletions in intron 10 as we had previously dem-
onstrated the presence of a purine-rich enhancer at the 5'
end and a silencer at the 3' end of intron 10, respectively.
Minigene pIRA contains both the enhancer and silencer
but the large internal deletion in intron 10 causes the jux-
taposition of the purine-rich enhancer with the 3' splice
site causing an increase in exon inclusion (Fig. 1B, pIRA).
Mutation of neither the 3' splice site of exon 11 nor the 5'
splice site in exon 10 in this background has a statistically
significant effect on exon skipping, as the exon is already
spliced efficiently due to the enhancer (Fig. 1B,
pIRA.MC17 & pIRA.MC3). Removal of the purine-rich
enhancer from minigene pIRA, resulting in minigene
pIRK, restores exon incorporation to levels comparable to
the parental minigene pIRB and once again mutation of
the 3' splice site caused the exon to be incorporated con-
stitutively in both cells (Fig. 1B, pIRK.MC7).
Intron 10 of the IR gene is spliced efficiently in-vitro
To analyze the recognition of exon 11 directly, we devel-
oped an in-vitro splicing assay. We had previously dem-
onstrated that splicing of intron 10 is the regulated step,
so templates were created which contained exon 10, seg-
ments of intron 10, and exon 11 of the IR gene. These RNA
templates (A, C, K, and L) were derived from minigenes
pIRA, pIRC, pIRK and pIRL that show differential skipping
of exon 11 when transfected into HepG2 and HeLa cells
[11]. The intron in template A (255 nt) contains both the
purine-rich enhancer and the inhibitor; template C (188
nt) contains the enhancer only, template K (151 nt) con-
tains the inhibitor only, and template L (84 nt) contains
neither (Fig. 2A). The presence of a 5' splice site on the 3'
end of a RNA template has been shown to enhance splic-
ing on other RNAs by facilitating exon-definition [33].
Consequently, splicing reactions were performed on tem-
plates lacking the terminal splice site, containing the 7-
nucleotide natural splice site, or containing a 7-nucleotide
consensus splice site. We were unable to obtain HepG2
nuclear extracts that were capable of supporting splicing.
Consequently, all of the in-vitro splicing reactions were
performed with HeLa extracts alone. The four template
RNAs were incubated with 40% HeLa nuclear extract for
60 min, and the spliced RNAs extracted and separated on
5% sequencing gels (Fig. 2B). Lariat intermediates were
identified by differential mobility on 8% gels (data not
shown). Similar experiments with a two-exon template
containing the downstream intron, or a three-exon tem-
plate containing both introns 10 and 11 failed to splice
under these conditions (data not shown), so subsequent
experiments focused on splicing of the upstream intron
10.
All four templates lacking the terminal 5' splice site were
spliced inefficiently (Fig. 2B left lanes). Templates A and L
are not spliced in the HeLa nuclear extract, and only very
weak splicing was observed for template K. Three lariat
intermediates, the free 5' exon, and the spliced product
were only observed on template C, which contains the
GA-enhancer and lacks the inhibitor. The spliced product
and the uppermost lariat intermediate also showed exo-
nucleolytic degradation. Inclusion of the natural splice
site on the four templates increased the efficiency of splic-
ing and generated splicing products 7-nucleotides longer
(Fig. 2B center lanes). The increased splicing is consistent
with the exon-definition model. There is also less degrada-
tion, which is consistent with the terminal splice site hav-
ing a protective effect on RNA stability. The relative
splicing efficiencies of these four templates mirrors the in-
vivo results with the exception of template L. This is the
smallest template and is spliced less efficiently in-vitro,
although it is spliced efficiently in-vivo. This is most likely
due to a size limitation with the in-vitro system, as introns
smaller than 80 nucleotides are not spliced efficiently in
HeLa extracts although they can be spliced in-vivo. Muta-
tion of the natural splice site to the consensus further
increased the efficiency of splicing on template K, but not
on templates A, C, & L (Fig. 2B right lanes). Data from
three experiments were combined to calculate the effi-
ciency of splicing (step 1 and step 2) and the results are
shown graphically (Fig. 2C). All of the regulation appears
to be at the first step of splicing as first and second step
splicing efficiencies are highly correlated.
Elimination of the splicing inhibitor from the template
RNA caused an increase in splicing on all templates irre-
spective of the presence of the terminal 5' splice site (Fig.
2C compare templates A and C). This is consistent with
the increase in exon 11 inclusion in minigenes pIRA and
pIRC in-vivo in HepG2 and HeLa cells. Elimination of the
purine-rich enhancer caused a decrease in intron splicing
only on the template containing the natural 5' splice site
from exon 11 (Fig. 2C compare templates Anat and Knat).
This is consistent with the behavior of minigenes pIRA
and pIRK in-vivo. The two templates A and K lacking the
terminal 5' splice site are not spliced, and the presence of
a consensus 5' splice site abrogates the effect of the
enhancer (Fig. 2C compare A & K, Acon & Kcon, respec-
tively). Mutation of this site to the consensus sequence
caused the exon to be spliced constitutively in-vivo (Fig.
1B), thus the in-vitro splicing assay recapitulates the regu-
lation seen in-vivo.
A simple explanation for the increased splicing efficiency
with deletion of the splicing inhibitor in intron 10 (i.e.
templates A & C) is that the splice site spacing is reduced,
which might increase the possibility of intronic defini-
tion. To exclude this explanation, we constructed aBMC Molecular Biology 2004, 5:7 http://www.biomedcentral.com/1471-2199/5/7
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In-vitro splicing of IR intron 10 templates Figure 2
In-vitro splicing of IR intron 10 templates. Panel A: Schematic of RNA templates used for in-vitro splicing. Left panel 
shows the percentage of skipping of exon 11 for four minigenes pIRA, pIRC, pIRK, and pIRL in HepG2 and HeLa cells in-vivo. 
Right panel shows the four templates generated by PCR amplification across exons 10 and 11 of the respective minigenes. The 
templates lacked the downstream intron and exon 12 that are present in the minigenes. The presence of the purine-rich 
enhancer (GA) and inhibitor (INH) are indicated, dashed lines represent deleted sequence. The size of the intron is shown. 
Panel B: Splicing of RNA templates either lacking the first seven nucleotides of intron 11 (left lanes), or containing the natural 5' 
splice site (center lanes) or a consensus 5' splice site (right lanes). All templates were incubated with 40% HeLa nuclear extract 
under splicing conditions for 60 min, the RNA extracted and separated on 5% sequencing gels. The RNA templates, spliced 
RNA (153 nt), and 5' exon (110 nt) are indicated by symbols on the right. Lariat intermediates were identified by differential 
mobility on 8% acrylamide gels and are indicated by asterisks. Panel C: Splicing efficiency was quantified by densitometric scan-
ning of autoradiographs. The natural 5' splice site is represented by nat, the consensus 5' splice site by con. Second step effi-
ciency was calculated from the ratio of spliced product to total RNA (spliced, 5' exon, and template, adjusted for labeling), first 
step efficiency was calculated from the ratio of spliced product plus 5' exon to total RNA. Values below the gel show the mean 
of three determinations and show the percent efficiency of each step for each template.
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template Clong that maintained the spacing of the splice
sites but eliminated the splicing inhibitor sequence by
including more sequence from the 5' end of the intron.
The Clong and C templates were spliced with equal effi-
ciency in the HeLa extract (Fig. 3), so we do not believe
intron length alters splicing efficiency on these templates.
Both the 5' and 3' splice sites are protected from RNaseH 
digestion in-vitro
The exon-definition model for splicing regulation pro-
poses that the inclusion of an exon in an mRNA is deter-
mined by the occupancy of the flanking 5' and 3' splice
sites due to base-pairing interactions with the U1 and U2
snRNPs. We investigated whether the 5' and 3' splice sites
were occupied on our insulin receptor templates using an
RNase H protection assay [34]. The four IR templates, A,
C, K, and L, containing the natural terminal 5' splice site
were probed with three oligonucleotides, one targeting
the 5' splice site of exon 10, another targeting the 3' splice
site upstream of exon 11, and the third targeting the
branch point sequence. The templates were incubated
with HeLa nuclear extract on ice or at 30°C for 30 min
before the addition of the oligonucleotides and RNase H.
The cleaved RNAs were separated by gel-electrophoresis
on 5% sequencing gels. The addition of RNase H alone
did not result in cleavage of the template RNAs (Fig. 4, left
lanes in each panel). Addition of RNase H plus any of the
three oligonucleotides caused the appearance of two frag-
ments on all four templates (Fig. 4). Incubation of the
templates at 30°C for 30 min to allow the formation of
splicing complexes, caused a decrease in the amount of
cleaved RNA and a concomitant increase in the amount of
un-cleaved RNA. Lariat intermediates and spliced prod-
ucts are also observed on templates A, C, and K following
incubation at 30°C verifying that splicing had occurred.
Thus, the splice sites on all four templates are protected
under these conditions. Occupancy of these sites is to be
expected as all templates are spliced, albeit with different
efficiencies, when the templates contain terminal 5' splice
sites (Fig. 2).
Similar RNase H protection assays were performed on
templates lacking the terminal 5' splice site or containing
a consensus splice site. In these experiments we used the
two oligonucleotides complementary to the 5' splice site
or the branch point sequence. The 5' splice site oligonu-
cleotide directed cleavage of all eight templates (Fig. 5A).
Incubation of the reactions at 30°C for 30 min to allow
formation of splicing complexes caused a decrease in the
extent of cleavage on all templates. No intermediates or
splicing products were observed on templates lacking the
splice site, as these are not spliced efficiently at 30 min
(Fig. 5A, left panel). Splicing products and lariat interme-
diates were observed for the templates containing consen-
sus splice sites confirming that splicing had occurred (Fig.
5A, right panel). Similarly, the branch point sequence oli-
gonucleotide directed cleavage of all templates, and
protection was observed after incubation under splicing
conditions (Fig. 5B). Here again, intermediates and splice
products were only observed on the templates containing
the consensus splice site (Fig. 5B, right panel).
To verify that the observed RNaseH protection was not
due to non-specific protein binding to the RNA, an oligo-
nucleotide to exon 10 upstream of the 5' splice site was
used. This oligonucleotide caused efficient cleavage of
four templates lacking the terminal splice site. Although
Increasing intron length does not reduce splicing efficiency  in-vitro Figure 3
Increasing intron length does not reduce splicing effi-
ciency in-vitro. RNA templates were generated from mini-
gene C and lacked the first seven nucleotides of intron 11. 
Clong contained an additional 67 nucleotides from the 5' end 
of intron 10 to maintain intron length at 255 nucleotides (see 
template A, Fig. 2). Both templates were incubated with 40% 
HeLa nuclear extract at 0°C or under splicing conditions for 
60 min, the RNA extracted and separated on 8% sequencing 
gels. The RNA templates, spliced RNA (153 nt), and 5' exon 
(110 nt) are indicated by symbols on the right. Lariat inter-
mediates are indicated by asterisksBMC Molecular Biology 2004, 5:7 http://www.biomedcentral.com/1471-2199/5/7
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Protection of the 5' and 3' splice sites and the branch point sequence Figure 4
Protection of the 5' and 3' splice sites and the branch point sequence. An RNaseH protection assay was used to 
probe occupancy of the splice sites on the IR templates. The four templates Anat, Cnat, Knat, and Lnat containing the natural 
terminal 5' splice site were incubated on ice or at 30°C for 30 min. Oligonucleotides complementary to the 5' splice site, the 3' 
splice site, or the branch point sequence (10 µM) were added followed by 2U RNaseH. Reactions were digested for 5 min at 
37°C, the RNA extracted and separated on 5% sequencing gels. The time of incubation at 30°C is indicated above each panel 
along with the oligo added. Open arrowheads indicate RNase cleavage products for each oligonucleotide. RNase protection 
results in a decrease in cleavage products and an increase in uncleaved RNA. Spliced product and 5' exon are visible in some 
reactions that have been incubated at 30°C. The small fragment from cleavage of probes Anat, Cnat and Knat at the 3' splice 
site has run off the gel in this experiment. The two cleavage products from the 5' splice site oligo on template Lnat co-migrate.
Time:        0     30    0    30    0    30    0    30           0    30     0    30     0    30    0    30   min
Oligo:             - 5’           3’          bps                         - 5’            3’          bps
RNA:                         Anat Cnat
Time:     0    30    0     30    0     30    0     30            0     30     0    30    0     30     0    30  min
Oligo:         - 5’             3’          bps                       - 5’             3’           bps
RNA:                      Knat LnatBMC Molecular Biology 2004, 5:7 http://www.biomedcentral.com/1471-2199/5/7
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Protection of the 5' splice site and branch point sequence of intron 10 Figure 5
Protection of the 5' splice site and branch point sequence of intron 10. The templates were derived from minigenes 
A, C, K, and L, and either lacked the terminal 5' splice site of exon 11 (A, C, K, & L, left panel) or contained a consensus termi-
nal splice site (Acon, Ccon, Kcon, & Lcon, right panel). The templates were incubated on ice or at 30°C for 30 min. An oligo-
nucleotide complementary to the 5' splice site of exon 10 was added followed by 2U RNase H. Reactions were digested for 5 
min at 37°C, the RNA extracted and separated on 5% sequencing gels. The time of incubation at 30°C is indicated above each 
panel along with the template added. Panel A: RNase H protection assay using the oligonucleotide complementary to the 5' 
splice site of exon 10. Panel B: RNase H protection assay using the oligonucleotide complementary to the branch point 
sequence of intron 10. Open arrowheads indicate cleavage products from each template. Spliced product and 5' exon can be 
seen in the right panel as the templates with the consensus splice site are spliced efficiently.
Time:       0    30    0    30     0   30    0    30             0    30     0   30     0    30    0   30    min
RNA:          A           C           K            L             Acon      Ccon     Kcon      Lcon
No 5’ splice site                                   Consensus 5’ splice site
A:
Time:    0    30   0    30   0   30   0    30                    0   30    0   30    0   30   0   30   min
RNA:          A          C          K          L                 Acon     Ccon    Kcon     Lcon
No 5’ splice site                            Consensus 5’ splice site
B:BMC Molecular Biology 2004, 5:7 http://www.biomedcentral.com/1471-2199/5/7
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the absolute recovery of RNAs varied, the ratio of cleaved
to uncleaved RNA was not altered by incubation under
splicing conditions at 30°C (Fig. 6A). Thus, this sequence
is not protected from digestion by RNaseH. Furthermore,
the initial step in spliceosomal assembly is recognition of
the 5' splice site by the U1 snRNP. To verify that the
observed protection at the 5' splice site is due to U1
snRNP binding, we performed RNaseH protection assays
in HeLa nuclear extracts that had been depleted for U1
snRNP by RNaseH-mediated digestion of the U1 snRNA.
No protection of the 5' splice site is observed in these
extracts (Fig. 6B). Similar results were obtained by
immuno-depleting extracts with an antibody to U1 70 K
protein (data not shown).
Splicing complexes are observed on all templates in-vitro 
irrespective of splicing
Although we had evidence for occupancy of the 5' splice
site by U1 snRNP, it was possible that the observed RNase
H protection was not related to the formation of splicing
Lack of protection by an oligonucleotide complementary to exon 10 Figure 6
Lack of protection by an oligonucleotide complementary to exon 10. Panel A: RNase H protection assay was per-
formed using an oligonucleotide complementary to exon 10. The templates were derived from minigenes A, C, K, and L, and 
lacked the terminal 5' splice site of exon 11. The templates were incubated on ice or at 30°C for 30 min. An oligonucleotide 
complementary to exon 10 was added followed by 2U RNase H. Reactions were digested for 5 min at 37°C, the RNA 
extracted and separated on 5% sequencing gels. The time of incubation at 30°C is indicated above each panel along with the 
template added. Open arrowheads indicate cleavage products from each template. The ratio of cleaved to uncleaved RNA is 
unaltered with this oligonucleotide. Panel B: the HeLa nuclear extract was pretreated with RNase H and an oligonucleotide 
complementary to the first 14 nucleotides of the U1 snRNA to deplete functional U1 snRNP. RNaseH protection assays were 
run as before using the oligonucleotide complementary to the 5' splice site using control (HeLa) or depleted (HeLa∆U1) 
extracts. Open arrowheads indicate cleavage products.
Time:   0    30    0   30    0   30    0   30    min
RNA:     A         C       K         L
No 5’ splice site
Time:   0   0  30         0        0        30   min
5’ Oligo:    - +    +          - +         +
Extract:    HeLa               HeLa∆ U1
A:                                        B:BMC Molecular Biology 2004, 5:7 http://www.biomedcentral.com/1471-2199/5/7
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Splicing complexes are assembled on all templates Figure 7
Splicing complexes are assembled on all templates. RNA templates were derived from minigenes A, C, K, and L and 
lacked the terminal 5' spice site of exon 11. The RNAs were incubated in 40 % HeLa nuclear extract on ice or for increasing 
times at 30°C to allow the formation of splicing complexes. Reactions were loaded directly onto 2% low-melting agarose gels 
(Panel A) or 4% native polyacrylamide gels (Panel B) and complexes separated by electrophoresis. Gels were dried under vac-
uum and exposed to film. The non-specific hnRNP complex H is indicated as well as the pre-spliceosomal complexes E and A. 
In Panel B, the higher order complexes B and C are indicated. In Panel C, the nuclear extract was pretreated with RNase H and 
an oligonucleotide complementary to the first 14 nucleotides of the U2 snRNA or a control oligonucleotide before complex 
assembly. In Panel D, the assembly reactions were performed in the absence or presence of ATP.BMC Molecular Biology 2004, 5:7 http://www.biomedcentral.com/1471-2199/5/7
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complexes. Consequently, complex assembly gels were
run to verify that splicing complexes were indeed
assembled on the templates. The four templates lacking
the terminal 5' splice site were used. Only template C con-
taining the purine-rich enhancer was spliced efficiently
under these circumstances (Fig. 2). These templates were
incubated with HeLa nuclear extract under splicing condi-
tions for increasing times, then loaded directly onto agar-
ose gels (Fig. 7A). Spliceosomal E complexes and A
complexes were observed on all templates, but identifica-
tion of higher complexes was not possible due to smear-
ing on the agarose gel. To achieve better resolution of the
complexes, splicing complex assembly assays were also
run on native polyacrylamide gels (Fig. 7B). A strong A
complex was observed on all templates, with much
weaker B and C complexes only visible on template C that
is actively spliced. We verified that the A complexes were
bona-fide splicing complexes by demonstrating that the
complexes were dependent on ATP and contained the U2
snRNP. Prior treatment of the nuclear extract with an oli-
gonucleotide directed against the U2 snRNA and RNaseH
to eliminate the U2 snRNP, prevented the formation of
the complex indicating that it contained U2 snRNP and
thus corresponds to the splicing A complex (Fig. 7C).
Treatment with a control oligonucleotide was without
effect. Omission of ATP from the splicing buffer prevented
the formation of the retarded A complex but did not alter
E complex formation (Fig. 7D). These findings confirm
the conclusion from the RNaseH protection experiments
that both the 5' and 3' splice sites are occupied on all tem-
plates in a pre-spliceosomal complex irrespective of
splicing.
Discussion
In this paper, we investigated how the small, 36-nucle-
otide, exon 11 of the insulin receptor gene is skipped to
generate a mature insulin receptor A isoform. We
demonstrated that skipping of exon 11 in-vivo requires
sub-optimal splice sites, as increasing the strength of
either the 5' or 3' splice site of exon 11 leads to constitu-
tive incorporation of the exon. In contrast, we found that
strengthening of the upstream and downstream splice
donor and acceptor sites on the neighboring exons leads
to decreased exon incorporation in-vivo. These results are
consistent with the exon-definition model proposed by
Berget, in which exons are defined in the context of
genomic sequence by both flanking splice sites [35]. Bind-
ing of the U1 snRNP to the 5' splice site of the exon facil-
itates recruitment of factors, such as SF1 and U2AF65/35
that recognize the upstream 3' splice site [36]. Stabiliza-
tion of the protein complex on the 3' splice site by these
bridging interactions across the exon then facilitates inter-
action with the U1 snRNP bound to the 5' splice site of the
previous exon allowing the intron to be defined [37,38].
This method of exon definition may have evolved to min-
imize the recognition of cryptic 3' splice sites that are not
associated with exons, as 3' splice site sequences are not
strictly defined and occur with high frequency throughout
the genome.
Small or microexons such as IR exon 11 impose a further
constraint on exon definition. Although the U1 snRNP
may recognize the 5' splice site on such a small exon, it
may not be able to interact productively with the 3' splice
site factors due to steric constraints over the small
distance. Usually in these cases, increasing the length of
the exon overcomes this constraint [39]. Exonic splicing
enhancers are occasionally found in such small exons,
and may compensate for the steric hindrance to exon def-
inition [40]. Consistent with this, we have previously
defined both positive and negative regulatory sequences
in exon 11 in the IR gene. The exon-definition model may
also explain the decrease in exon 11 recognition when
splice sites on the flanking exons are strengthened. Splic-
ing of RNA is co-transcriptional and generally proceeds in
a linear manner along the RNA. Each exon may itself be
defined on the nascent transcript by the RNA polymerase
complex. If assembly of the U1/U2 snRNPs and/or other
splicing factors that define a particular exon is slow,
whether due to steric constraints or weak splice sites, the
next downstream exon may be defined preferentially. This
kinetic competition could lead to skipping of the exon.
We obtained similar results when splicing of exon 11 was
studied in-vitro. Efficient splicing was only seen if a termi-
nal 5' splice site was included in the RNA. In the absence
of this terminal splice site, only a template that contained
a purine-rich intronic enhancer was spliced efficiently. In
the presence of the natural 5' splice site, all templates were
spliced but to different extents. Again, the most efficiently
spliced template contained the intronic enhancer, a tem-
plate containing an inhibitory element was spliced less
efficiently, and a template containing both was intermedi-
ate. Addition of a consensus splice site to the templates
further increases the efficiency of splicing but the effect of
the intronic inhibitor is lost, as is seen in-vivo. Thus, the
in-vitro splicing results are also consistent with the exon-
definition model.
Although we do not know how the intronic enhancer pro-
motes splicing in the absence of the terminal splice site,
two scenarios can be envisioned. The fact that this
enhancer is very GA rich might indicate that SR proteins
functionally replace the terminal 5' splice site and stabi-
lize binding of U2AF to the 3' splice site. Exonic binding
sites for the SR proteins SF2/ASF and SC35 have been
shown to stabilize binding of U2AF to 3' splice sites
[24,26,27,30]. One argument against this model is that
co-transfection of expression vectors for SRp20, SC35,
SRp40, SRp55, or SRp75 did not alter exon incorporationBMC Molecular Biology 2004, 5:7 http://www.biomedcentral.com/1471-2199/5/7
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in-vivo (data not shown). Unfortunately, this experiment
is of limited value as most SR proteins are in excess, so
further overexpression might not show a phenotype.
Depletion of individual or groups of SR proteins would be
more convincing but is harder to achieve. Alternatively,
the enhancer may recruit the U1 snRNP directly, inde-
pendently of the terminal 5' splice site. McCullough and
Berget have shown that the U1 snRNP helps to define
small exons by base-pairing with intronic GGG triplets
[41]. The purine-rich intronic enhancer in the IR gene
contains nine GGG triplets, so targeting the U1 snRNP to
the enhancer may stabilize the binding of U2AF to the 3'
splice site in the same manner as when the U1 snRNP is
bound to the 5' splice site of the exon. This enhancement
may be position dependent, however, as insertion of ran-
dom genomic sequences containing GGG sequences into
exons has been shown to inhibit splicing [42].
Noticeably different results were obtained, however,
when we examined splice site occupancy and splicing
complex assembly. Using RNaseH to probe occupancy of
the 5' and 3' splice sites, we observed that these sites were
occupied on all of the splicing templates irrespective of
how the templates splice in-vitro. This finding was con-
firmed by complex assembly assays. The spliceosomal A
complex was observed on all templates, even those that
did not splice efficiently. We verified that these corre-
sponded to bona-fide pre-spliceosomal complexes by
demonstrating that they were ATP-dependent and con-
tained the U2 snRNP. This implies that the regulation of
splicing on this template must occur after the initial recog-
nition of the splice sites but before the first catalytic step,
as there was good concordance between splicing interme-
diates and products for all templates. These findings are
not consistent with the exon-definition model. However,
a number of studies have questioned this model. Recogni-
tion of 5' splice sites by the U1 snRNP does not always
correlate with splicing efficiency, especially for substrates
that contain alternative 5' splice sites. Nasim et al. demon-
strated that repression of proximal 5' splice site use by
hnRNP A1 was related to RNA looping and not U1 snRNP
binding [43]. This may be a special case as the looping was
mediated by duplicate high affinity hnRNP A1 binding
sites flanking the alternative exon and could be mimicked
by inverted repeat sequences. Eperon et al. showed that
the SF2/ASF-mediated enhancement of proximal 5' splice
site use was accompanied by enhanced binding of U1
snRNP to both 5' splice sites, but the hnRNP A1-mediated
repression of proximal 5' splice site use was related to
reduced U1 snRNP binding to both sites [44]. They con-
cluded that shift from the use of the distal 5' splice site by
the addition of hnRNP A1 resulted not from a reduction
in U1 snRNP binding, but by sequestration of the site.
At the 3' end of the intron, recent publications have also
questioned the U2AF-recruitment hypothesis. Blencowe
and co-workers found that the splicing accessory factor
U2AF-65 bound to a double-sex (dsx)pre-mRNA irrespec-
tive of splicing [36]. This mRNA, which lacked the exonic
splicing enhancer, was not spliced in-vitro, but U2AF-65
was still bound to the 3' splice site. The binding of U2AF-
65 required the presence of the U1 snRNP on the 5' splice
site but did not require SR proteins. It's possible that
another protein such as the BBP/SF1 was mediating the
interaction between the 5' and 3' splice sites in the
absence of SR proteins. The recruitment of SR proteins
and splicing of the RNA was still dependent on the
enhancer, however, suggesting a role for SR proteins other
than to recruit U2AF-65. The authors suggested that this
function may be to recruit the splicing co-activator
SRm160/300 that is required for the formation of a func-
tional spliceosome.
The recruitment model of exon-definition is attractive as
it makes little teleological sense to assemble splicing com-
plexes on non-functional splice sites. However, spliceo-
somal assembly on a number of decoy sites has been
shown. Cote et al. showed that non-productive splicing
complexes containing the U2 snRNP are formed between
the 5' splice site of exon 9 and a pseudo 3' splice site
sequence in the downstream intronic inhibitory element
in the caspase 2 pre-mRNA [45]. Similar dead-end com-
plexes are formed on the immunoglobulin M2 exonic
silencer [46]. Sun et al. have investigated the splicing of
pseudoexons that are present through out the genome
[47]. These pseudoexons have good matches to consensus
splice site sequences but are not used. They showed that
both the 5' splice site and the polypyrimidine tract are
defective and identified an upstream inhibitory element.
The mechanism for inhibition is not known but the
authors suggest that it might involve binding of U2 snRNP
in a dead-end complex. A potential pseudo 3' splice site
also exists in intron 10 of the IR gene (U16GACAG). While
we have no evidence for assembly on this site, it is worth
noting that internal deletions of intron 10, which show
enhanced exon incorporation in-vivo, lack this pseudo
splice site.
Our findings raise a number of questions. Firstly, why are
some pre-spliceosomal complexes non-functional on
selected IR templates? One possible explanation is that
splicing of exon11 in-vitro is regulated either at the level
of recruitment of the U4/5/6 tri-snRNP or the subsequent
rearrangements to form the active splicing complex, as has
been proposed for dsx  splicing. In this model, factors
binding to the intronic regulatory sequences could
stabilize the U1 snRNP interaction at the 5' splice site and
prevent the stable accommodation of the tri-snRNP com-
plex. This is supported by a recent study defining 5' spliceBMC Molecular Biology 2004, 5:7 http://www.biomedcentral.com/1471-2199/5/7
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sites by functional selection. Lund and Kjems highlighted
an inherent discontinuity between stable complex A for-
mation and progression to complex B and active splicing
[48]. In their experiments, extended complementarity
between the 5' splice site and the U1 snRNA promoted
complex A formation but inhibited subsequent splicing.
Truncation of the U1 snRNA allowed a rapid transition
from complex A to complex B and restored splicing. The
authors concluded that stable U1 snRNA binding is
advantageous for assembly of commitment complexes,
but inhibitory for the entry of the U4/5/6 tri-snRNP due
to delayed release of the U1 snRNP.
Our minigene transfection studies are consistent with the
exon-definition model, but the in-vitro studies suggest
that regulation may not be explained by the simple
recruitment model. How can we reconcile the in-vivo and
in-vitro results? The finding that the splice sites are occu-
pied in-vitro does not necessarily imply the sites are occu-
pied in-vivo. It may be that competitive splice site
recognition is the dominant regulatory mechanism, but
the slower kinetics of splicing in-vitro allows assembly of
splicing complexes on weak splice sites that would other-
wise be ignored. Alternatively, the deleted intron used for
in-vitro splicing studies may have caused a shift from exon
definition to intron definition. Spliceosomal complexes
could have assembled due to interactions across introns,
which would not occur in-vivo where the introns are 2.3
kB and 9 Kb. These complexes may be functionally dis-
tinct from complexes assembled across exons.
Conclusion
We have demonstrated that alternative splicing of exon 11
of the IR gene in-vivo involves sub-optimal splice sites
consistent with the exon-definition model. However, we
observed occupancy of the 5' splice site by U1 snRNP, and
the formation of non-functional spliceosomal A com-
plexes, containing U2-snRNP, on exon 11 RNA templates
in-vitro. This observation suggests that the regulation of
splicing of this exon in-vitro is not explained by the sim-
ple recruitment model. Further studies to analyze splice
site recognition and spliceosomal complex assembly in-
vivo will be required to resolve these questions.
Methods
Reagents
Cell culture media and antibiotics were from Gibco
(Grand Island, NY), reverse transcriptase (SuperScript II),
Lipofectamine Plus and oligo-dT were purchased from
Life Technologies (Rockville, MD) and fetal calf serum
from Omega Scientific (Tarzana, CA). Nuclear extracts
were purchased from Accurate Chemical & Scientific Cor-
poration (Westbury, NY). RNase H was from USB Corpo-
ration (Cleveland, OH). RNA cap analog was purchased
from New England Biolabs (Beverley, MA). Nucleotides
were purchased from Amersham/Pharmacia (Piscataway,
NJ), T7 RNA Polymerase was purchased from Promega
(Madison, WI). The QuickChange mutagenesis kit and
CalPhos Maximizer transfection kit were from Stratagene
(La Jolla, CA). All plasmids were constructed using stand-
ard techniques. Point mutations were introduced into
minigenes using the QuickChange mutagenesis kit and
verified by dideoxysequencing. All other reagents were
purchased from Sigma Chemical (St. Louis, MI) or Fisher
Scientific (Pittsburgh, PA).
Cell culture and transfections
HepG2 and HeLa cells were maintained at 37°C in a 5%
CO2 environment. HepG2 and HeLa cells were cultured in
MEM-Earle's medium supplemented with 10% fetal
bovine serum and gentamycin sulfate antibiotic. Cells
were plated in 6-well dishes for transfection. Hela cells
were transfected using the calcium phosphate method.
HepG2 cells were transfected with Lipofectamine Plus fol-
lowing the manufacturers protocol. Splice site strength
was calculated using Shapiro and Senapathy Splice Score
http://home.snafu.de/probins/Splice/splice.html.
RT-PCR analysis
RNA was extracted from transfected cells using RNAzolB
(TelTest, TX) following manufacturers directions and pre-
cipitated twice. To avoid interference from partially
spliced intermediates, RNA was purified by mRNA Cap-
ture (Roche Biosciences, IN) before reverse transcription
using SuperScript II and oligo-dT as primer. PCR amplifi-
cation of IR splice products derived from the minigenes
was performed as published previously. Splice products
were resolved on 4% agarose gels (Latitude HT, BioWhit-
taker Molecular Applications, Rockland, ME) and quanti-
fied using a Kodak EDAS290 imaging system.
In-vitro splicing
Templates for in-vitro transcription were generated by
PCR from minigenes A, C, K, and L [11]. The 5' PCR
primer contained a T7 promoter to allow in-vitro tran-
scription. Three different 3' PCR primers were used to gen-
erate templates either lacking the 5' splice site on exon 11,
or containing the 7 nucleotide natural splice site (GUAU-
GAC), or a 7 nucleotide consensus splice site (GUAA-
GUA). Templates were gel purified before use.
Capped and labeled pre-mRNA templates were tran-
scribed using T7 RNA polymerase and 32P-GTP as pub-
lished previously [49]. RNAs were gel-purified before use.
Splicing reactions were performed by incubating 20 fmol
of pre-mRNA at 30°C in the presence of 0.5 mM ATP, 8
mM MgCl2, 2.6% polyvinylalcohol, 60 mM KCl and 40%
HeLa nuclear extract. Reaction products were extracted
with phenol and precipitated in ethanol before electro-
phoresis on 5% sequencing gels. Gels were exposed toBMC Molecular Biology 2004, 5:7 http://www.biomedcentral.com/1471-2199/5/7
Page 14 of 15
(page number not for citation purposes)
film at -70°C for different times. Quantification of splic-
ing efficiency was performed by densitometric scanning of
autoradiographs (Agfa Arcus II scanner and Kodak 1D
software, Ver. 3.5) from multiple exposures of the gels.
First step splicing efficiency was defined as the sum of free
5' exon plus spliced mRNA versus the total of free 5' exon,
spliced mRNA and unspliced RNA template. Second step
efficiency was defined as the spliced mRNA versus the
total of free 5' exon, spliced mRNA plus unspliced RNA.
All bands intensities were adjusted for the number of G
residues.
RNase H protection assay
Duplicate splicing reactions were set up as above. One
reaction was kept on ice while the other was incubated at
30°C for 30 min to allow the formation of splicing com-
plexes. Oligonucleotides were added to a final concentra-
tion of 10 µM, then 2 U RNase H was added and the
reaction incubated at 37°C for 5 min. Reaction products
were extracted and analyzed by gel electrophoresis as
before. The following oligonucleotides were used: 5'
splice site, GTCCTGACCTGG; branch point sequence,
CCTTTGAGGACAG; 3' splice site, CTGTGGAAACAAAAC;
exon 10 control, GTGGGGACGAAA. The percentage of
uncleaved RNA was determined by densitometric scan-
ning of autoradiographs for both cleavage products and
the remaining uncleaved RNA. Relative protection was
calculated as the ratio of the percentage of uncleaved RNA
in reactions incubated at 30°C versus the percentage of
uncleaved RNA in reactions kept at 0°C. In some experi-
ments, the U1 snRNP was depleted by treating the nuclear
extract for 20 min at 30°C with 2 U RNase H and 10 µM
of an oligonucleotide complementary to nucleotides 1–
14 of the U1 snRNA (TGCCAGGTAAGTAT).
Spliceosomal complex assembly assay
Splicing reactions were performed as above in 40% HeLa
nuclear extract. At the appropriate times, heparin was
added to 5 µg/µl and the reaction analyzed on 5% non-
denaturing, non-reducing acrylamide gels or 2% low-
melting agarose gels. Acrylamide gels were run for 16 h at
4 W at room temperature, agarose gels were run for 3.5 h
at 70 V at 4°C. Gels were fixed and dried under vacuum
then exposed to film. In some experiments, the U2 snRNP
was depleted by treating the nuclear extract for 20 min at
30°C with 2 U RNase H and 10 µM of an oligonucleotide
complementary to nucleotides 1–15 of the U2 snRNA
(GGCCGAGAAGCGAT) or a control oligonucleotide
(GGGGTGAATTCTTTGCCA). In experiments in the
absence of ATP, the nuclear extract was incubated at 30°C
for 20 min before the addition of RNA to deplete residual
ATP in the nuclear extract.
Abbreviations
IR, insulin receptor; IGF, insulin-like growth factor;
snRNA, small nuclear RNA; snRNP, small nuclear ribonu-
cleoprotein particle; SR protein, serine-arginine rich splic-
ing factor
Authors' contributions
NJGW performed the in-vitro splicing reactions and com-
plex assembly experiments. LGE performed the transfec-
tions and RT-PCR assays. MC and LR constructed
mutations. SLC supervised the in-vitro splicing, RNaseH
protection and complex assembly experiments and pro-
vided essential reagents and advice.
Acknowledgements
This work was supported by a Merit Review Award from the Department 
of Veterans Affairs (to N.J.G.W.) and by the Joint Research Board of St. 
Bartholomew's Hospital (to S.L.C.). N.J.G.W. is a faculty member of the 
UCSD Biomedical Sciences Graduate Program.
References
1. Moller DE, Yokota A, Caro JF, Flier JS: Tissue-specific expression
of two alternatively spliced insulin receptor mRNAs in man.
MolEndocrinol 1989, 3:1263-1269.
2. Norgren S, Arner P, Luthman H: Insulin receptor ribonucleic
acid levels and alternative splicing in human liver, muscle,
and adipose tissue: tissue specificity and relation to insulin
action. JClinEndocrinolMetab 1994, 78:757-762.
3. Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, Gold-
fine ID, Belfiore A, Vigneri R: Insulin receptor isoform A, a newly
recognized, high-affinity insulin-like growth factor II recep-
tor in fetal and cancer cells. Mol Cell Biol 1999, 19:3278-3288.
4. Kellerer M, Sesti G, Seffer E, Obermaier-Kusser B, Pongratz DE,
Mosthaf L, Haring HU: Altered pattern of insulin receptor iso-
types in skeletal muscle membranes of type 2 (non-insulin-
dependent) diabetic subjects. Diabetologia 1993, 36:628-632.
5. Kosaki A, Webster NJ: Effect of dexamethasone on the alterna-
tive splicing of the insulin receptor mRNA and insulin action
in HepG2 hepatoma cells. J Biol Chem 1993, 268:21990-21996.
6. Mosthaf L, Vogt B, Haring HU, Ullrich A: Altered expression of
insulin receptor types A and B in the skeletal muscle of non-
insulin-dependent diabetes mellitus patients. Proc Natl Acad Sci
USA 1991, 88:4728-4730.
7. Norgren S, Zierath J, Galuska D, Wallberg-Henriksson H, Luthman H:
Differences in the ratio of RNA encoding two isoforms of the
insulin receptor between control and NIDDM patients. The
RNA variant without Exon 11 predominates in both groups.
Diabetes 1993, 42:675-681.
8. Norgren S, Li LS, Luthman H: Regulation of human insulin recep-
tor RNA splicing in HepG2 cells: effects of glucocorticoid and
low glucose concentration.  BiochemBiophysResCommun 1994,
199:277-284.
9. Philips AV, Timchenko LT, Cooper TA: Disruption of splicing reg-
ulated by a CUG-binding protein in myotonic dystrophy. Sci-
ence 1998, 280:737-741.
10. Savkur RS, Philips AV, Cooper TA: Aberrant regulation of insulin
receptor alternative splicing is associated with insulin resist-
ance in myotonic dystrophy. Nat Genet 2001, 29:40-47.
11. Kosaki A, Nelson J, Webster NJ: Identification of intron and exon
sequences involved in alternative splicing of insulin receptor
pre-mRNA. J Biol Chem 1998, 273:10331-10337.
12. Sharp PA: Split genes and RNA splicing. Cell 1994, 77:805-815.
13. Moore MJ: Intron recognition comes of AGe. Nat Struct Biol
2000, 7:14-16.
14. Valcarcel J, Gaur RK, Singh R, Green MR: Interaction of U2AF65
RS region with pre-mRNA branch point and promotion of
base pairing with U2 snRNA. Science 1996, 273:1706-1709.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Molecular Biology 2004, 5:7 http://www.biomedcentral.com/1471-2199/5/7
Page 15 of 15
(page number not for citation purposes)
15. Zamore PD, Patton JG, Green MR: Cloning and domain structure
of the mammalian splicing factor U2AF.  Nature 1992,
355:609-614.
16. Merendino L, Guth S, Bilbao D, Martinez C, Valcarcel J: Inhibition of
msl-2 splicing by Sex-lethal reveals interaction between
U2AF35 and the 3' splice site AG. Nature 1999, 402:838-841.
17. Wu S, Romfo CM, Nilsen TW, Green MR: Functional recognition
of the 3' splice site AG by the splicing factor U2AF35. Nature
1999, 402:832-835.
18. Zorio DA, Blumenthal T: Both subunits of U2AF recognize the
3' splice site in Caenorhabditis elegans.  Nature 1999,
402:835-838.
19. Abovich N, Rosbash M: Cross-intron bridging interactions in
the yeast commitment complex are conserved in mammals.
Cell 1997, 89:403-412.
20. Berglund JA, Chua K, Abovich N, Reed R, Rosbash M: The splicing
factor BBP interacts specifically with the pre-mRNA branch-
point sequence UACUAAC. Cell 1997, 89:781-787.
21. Rain JC, Rafi Z, Rhani Z, Legrain P, Kramer A: Conservation of
functional domains involved in RNA binding and protein-
protein interactions in human and Saccharomyces cerevi-
siae pre-mRNA splicing factor SF1. RNA 1998, 4:551-565.
22. Kramer A: The structure and function of proteins involved in
mammalian pre-mRNA splicing.  Annu Rev Biochem 1996,
65:367-409.
23. Lopez AJ: Alternative splicing of pre-mRNA: developmental
consequences and mechanisms of regulation. Annu Rev Genet
1998, 32:279-305.
24. Zuo P, Maniatis T: The splicing factor U2AF35 mediates critical
protein-protein interactions in constitutive and enhancer-
dependent splicing. Genes Dev 1996, 10:1356-1368.
25. Kohtz JD, Jamison SF, Will CL, Zuo P, Luhrmann R, Garcia-Blanco
MA, Manley JL: Protein-protein interactions and 5'-splice-site
recognition in mammalian mRNA precursors. Nature 1994,
368:119-124.
26. Wu JY, Maniatis T: Specific interactions between proteins
implicated in splice site selection and regulated alternative
splicing. Cell 1993, 75:1061-1070.
27. Lavigueur A, La Branche H, Kornblihtt AR, Chabot B: A splicing
enhancer in the human fibronectin alternate ED1 exon inter-
acts with SR proteins and stimulates U2 snRNP binding.
Genes Dev 1993, 7:2405-2417.
28. Manley JL, Tacke R: SR proteins and splicing control. GenesDev
1996, 10:1569-1579.
29. Staknis D, Reed R: SR proteins promote the first specific rec-
ognition of Pre-mRNA and are present together with the U1
small nuclear ribonucleoprotein particle in a general splicing
enhancer complex. Mol Cell Biol 1994, 14:7670-7682.
30. Wang Z, Hoffmann HM, Grabowski PJ: Intrinsic U2AF binding is
modulated by exon enhancer signals in parallel with changes
in splicing activity. RNA 1995, 1:21-35.
31. Chan RC, Black DL: The polypyrimidine tract binding protein
binds upstream of neural cell-specific c-src exon N1 to
repress the splicing of the intron downstream. Mol Cell Biol
1997, 17:4667-4676.
32. Valcarcel J, Singh R, Zamore PD, Green MR: The protein Sex-
lethal antagonizes the splicing factor U2AF to regulate alter-
native splicing of transformer pre-mRNA.  Nature 1993,
362:171-175.
33. Talerico M, Berget SM: Effect of 5' splice site mutations on splic-
ing of the preceding intron. Mol Cell Biol 1990, 10:6299-6305.
34. Eperon IC, Ireland DC, Smith RA, Mayeda A, Krainer AR: Pathways
for selection of 5' splice sites by U1 snRNPs and SF2/ASF.
EMBO J 1993, 12:3607-3617.
35. Berget SM: Exon recognition in vertebrate splicing. J Biol Chem
1995, 270:2411-2414.
36. Li Y, Blencowe BJ: Distinct factor requirements for exonic
splicing enhancer function and binding of U2AF to the
polypyrimidine tract. J Biol Chem 1999, 274:35074-35079.
37. Achsel T, Shimura Y: Factors involved in the activation of pre-
mRNA splicing from downstream splicing enhancers.  JBio-
chem(Tokyo) 1996, 120:53-60.
38. Chabot B: Directing alternative splicing: cast and scenarios.
Trends Genet 1996, 12:472-478.
39. Black DL: Does steric interference between splice sites block
the splicing of a short c-src neuron-specific exon in non-neu-
ronal cells? Genes Dev 1991, 5:389-402.
40. Carlo T, Sterner DA, Berget SM: An intron splicing enhancer
containing a G-rich repeat facilitates inclusion of a verte-
brate micro-exon. RNA 1996, 2:342-353.
41. McCullough AJ, Berget SM: An intronic splicing enhancer binds
U1 snRNPs to enhance splicing and select 5' splice sites. Mol
Cell Biol 2000, 20:9225-9235.
42. Fairbrother WG, Chasin LA: Human genomic sequences that
inhibit splicing. Mol Cell Biol 2000, 20:6816-6825.
43. Nasim FU, Hutchison S, Cordeau M, Chabot B: High-affinity
hnRNP A1 binding sites and duplex-forming inverted
repeats have similar effects on 5' splice site selection in sup-
port of a common looping out and repression mechanism.
RNA 2002, 8:1078-1089.
44. Eperon IC, Makarova OV, Mayeda A, Munroe SH, Caceres JF, Hay-
ward DG, Krainer AR: Selection of alternative 5' splice sites:
role of U1 snRNP and models for the antagonistic effects of
SF2/ASF and hnRNP A1. Mol Cell Biol 2000, 20:8303-8318.
45. Cote J, Dupuis S, Jiang Z, Wu JY: Caspase-2 pre-mRNA alterna-
tive splicing: Identification of an intronic element containing
a decoy 3' acceptor site. Proc Natl Acad Sci U S A 2001, 98:938-943.
46. Kan JL, Green MR: Pre-mRNA splicing of IgM exons M1 and M2
is directed by a juxtaposed splicing enhancer and inhibitor.
Genes Dev 1999, 13:462-471.
47. Sun H, Chasin LA: Multiple splicing defects in an intronic false
exon. Mol Cell Biol 2000, 20:6414-6425.
48. Lund M, Kjems J: Defining a 5' splice site by functional selection
in the presence and absence of U1 snRNA 5' end. RNA 2002,
8:166-179.
49. Mayeda A, Krainer AR: Mammalian in vitro splicing assays. Meth-
ods Mol Biol 1999, 118:315-321.